OncoPharm

The FDA has been a bunch of busy bees with new approvals:
1. Sonrotoclax, an exciting new BCL2 inhibitor approved for 3rd-line Mantle Cell Lymphoma
2. An all PO regimen of decitabine/cedazuridine + venetoclax is approved for AML.
3. Zenoctuzumab gets an FDA approval for cholangiocarcinoma with an efficacy patient population = 19
4. T-DXd is a good drug and continues to pile on FDA approvals
5. Adjuvant atezolizumab in bladder cancer is approved in conjunction with ctDNA serial monitoring to determine who gets treatment

Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm

This week's pod has lots of updates!

IMHOTEP: Pre-operative doses of pembrolizumab lead to significant pCR rates in dMMR colon cancer. https://doi.org/10.1200/JCO-25-02169

Real world rates of PJP suggest room for improvement in prophylaxis, especially those on corticosteroids + additional immunosuppressants. https://doi.org/10.1177/10600280261443794

Daraxonrasib given expanded access by FDA before approval: https://www.fda.gov/news-events/press-announcements/fda-permits-expanded-access-investigational-pancreatic-cancer-drug

And yes, the ivermectin boom was real: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2848862

Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm

The latest FDA drug approval is vepdegestrant, a heterobifunctional protein degrader, for ESR1 mutated breast cancer. We discuss what that actually means and some possible implications for clinical practice.

Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm

This is our 1st in a series of podcasts/videos to role out once or twice a year on therapeutic targets in cancer. First up - Trop2

Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm

Video with slides: https://youtu.be/mrDQyYkaF7A

This week we highlight some promising clinical research in the pancreatic cancer space.

Daraxonrasib has shown OS benefit vs. chemo in the 2nd-line setting of metastatic pancreatic cancer compared to investigator's choice chemotherapy. Hopefully, we will get the abstract soon and publication shortly thereafter.

A personalized mRNA vaccine for early-stage pancreatic cancer has some encouraging results (for those patients who mounted a sizable immune response to the vaccine).

Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm